D

rug makers may want to strap on their parachutes — another patent cliff lies ahead.

The phrase, of course, refers to the loss of patent protection on big-selling drugs that ravaged the pharmaceutical industry several years ago. As the companies began facing generic competition, many cut jobs and closed plants, refocused research efforts, and scrambled for deals to replenish pipelines.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.